Targeted immunotherapy, particularly immune checkpoint inhibitor therapy, such as PD-1, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 inhibitors, has demonstrated positive therapeutic effects in advanced bladder cancer (145–147). The gene discussed is PDCD1; the disease is urinary bladder carcinoma.